Spotlighting Organoids & PDX Platforms for Targeting Adaptive Responses in Cancer Therapy
- Development and application of organoids and PDX models to study adaptive responses to targeted therapies and immunotherapies in prostate cancer
- Elucidating which model from organoids and PDX mice is more representative of prostate cancer
- Using clinical data from Phase I and II trials to better understand mechanism of resistance and pathology to develop better therapeutic strategies with a focus on enhancing clinical relevance and therapeutic precision